CN109432012B - Preparation method of baicalein drug-loaded nanorod - Google Patents
Preparation method of baicalein drug-loaded nanorod Download PDFInfo
- Publication number
- CN109432012B CN109432012B CN201811554429.XA CN201811554429A CN109432012B CN 109432012 B CN109432012 B CN 109432012B CN 201811554429 A CN201811554429 A CN 201811554429A CN 109432012 B CN109432012 B CN 109432012B
- Authority
- CN
- China
- Prior art keywords
- baicalein
- drug
- solution
- loaded
- nanorod
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a preparation method of a baicalein drug-loaded nanorod, belonging to the field of pharmacy, and the method comprises the following steps: firstly, weighing baicalein and pectin respectively, adding into a glass container, adding a phosphoric acid buffer solution, immersing the glass container in a constant-temperature water bath at 50 ℃, and uniformly mixing by magnetic stirring to obtain a mixed solution I; then, dropwise adding a Ca (OH) ₂ aqueous solution into the mixed solution I, and heating for 1h at the temperature of 50 ℃; then dropwise adding NaHCO ₃ aqueous solution, and heating for 3 hours at 50 ℃ to obtain mixed solution II; and finally adding the baicalein into the mixed solution II, continuously magnetically stirring for 24 hours at the temperature of 50 ℃, cooling, filling into a dialysis bag, and dialyzing for 24 hours in phosphoric acid buffer solution at the temperature of 20 ℃ to obtain the baicalein drug-loaded nanorod. The baicalein drug-loaded nanorod prepared by the preparation method shows good targeting property, histocompatibility, low toxic and side effects and slow-release function.
Description
Technical Field
The invention belongs to the field of pharmacy, and particularly relates to a preparation method of a baicalein drug-loaded nanorod.
Background
The nano drug-loading system is a complete system formed by encapsulating, dispersing and adsorbing drugs in a polymer, wherein the particle size of the prepared nano structure is 1-1000 nm. The flavonoid compound is a general name of a compound with a chromone ring and a benzene ring as basic structures, is a derivative of chromone or chromane, and is a yellow pigment derived by taking flavone (2-phenyl chromone) as a parent nucleus. The nano drug-carrying system is a novel drug-delivery dosage form, the size of the drug-carrying nano particles is similar to that of the protein of the organism, the drug-carrying nano particles can easily permeate cell membranes and enter tissue fluid without being rejected by the organism, and the drug-carrying nano particles have good histocompatibility. The medicament is encapsulated to realize the slow release effect and the effect of stabilizing the medicament, so that the local aggregation degree of the medicament is reduced, and the adverse reaction to an organism can be reduced. The targeting property of the medicine can be improved by surface modification of the medicine or encapsulation of the medicine in a carrier material with special affinity to different tissues of an organism. And the carrier material is easy to obtain, basically is natural and synthetic high polymer, and the preparation process has mild conditions and simple method, and can be prepared without special precise instruments and equipment. The research on the nano medicine carrying system at home and abroad has great effect, stable and reliable process route, skillful method and stable quality, is suitable for industrial production and living requirements, and has direct medicine treatment potential.
Baicalein (baicalein) is a flavonoid compound, and is one of the main effective components of Scutellaria baicalensis Georgi of Labiatae. Has the functions of resisting bacteria and virus, inhibiting inflammatory reaction, protecting liver, benefiting gallbladder, promoting urination, resisting cancer, etc. and has excellent clinical application value. Baicalein has extremely low oral toxicity, but intravenous injection has much higher toxicity than oral gavage. In view of the toxicity of baicalein in intravenous injection, the carrier system prepared from the baicalein has the advantages of targeting property, good histocompatibility, low toxic and side effects, slow release function and the like. The preparation of nano-scale pharmaceutical systems requires rigorous preparation processes.
Disclosure of Invention
In view of the above situation, the invention aims to provide a preparation method of a baicalein drug-loaded nanorod, and the baicalein drug-loaded nanorod prepared by the preparation method shows good targeting property, good histocompatibility, low toxic and side effects and a slow release function.
In order to achieve the purpose, the invention adopts the specific scheme that:
a preparation method of a baicalein drug-loaded nanorod comprises the following steps:
step one, respectively weighing 0.01g of baicalein and 0.1g of pectin, adding into a glass container, adding 20mL of phosphoric acid buffer solution, soaking the glass container in a constant-temperature water bath at 50 ℃, and uniformly mixing by magnetic stirring for 0.5h to obtain a mixed solution I;
step two, dropwise adding 8mL of Ca (OH) with the concentration of 0.02mol/L into the mixed solution I2Heating the aqueous solution at 50 deg.C for 1 hr; then 8mL of NaHCO with the concentration of 0.03mol/L is added dropwise3Heating the aqueous solution for 3 hours at 50 ℃ to obtain a mixed solution II;
step three, adding 0.01g of baicalein into the mixed solution II, continuously magnetically stirring for 24 hours at the temperature of 50 ℃, and then placing the mixture into a water bath at the normal temperature of 20 ℃ for cooling for 0.5 hour to obtain a reaction mixture; and putting the reaction mixture into a dialysis bag, and dialyzing in 500mL of phosphoric acid buffer solution at 20 ℃ for 24h to obtain the baicalein drug-loaded nanorod.
As a further optimization of the above protocol, the pH of the phosphate buffer solution was 6.7.
As a further optimization of the above scheme, the preparation method of the phosphoric acid buffer solution comprises the following steps: 7.957g of sodium dihydrogen phosphate and 17.549g of disodium hydrogen phosphate powder are respectively weighed and respectively dissolved in distilled water, and then the solution is transferred to a 500mL volumetric flask and diluted with distilled water to a constant volume of 500mL, thus obtaining the phosphoric acid buffer solution.
Has the advantages that:
the baicalein medicine carrying nanorod prepared by the method can effectively delay the release of the medicine, has a certain slow release effect, can reduce toxic and side effects, and improves the bioavailability of the medicine. The baicalein rod-shaped nano drug-carrying system has high encapsulation rate, and the encapsulation rate of the pectin baicalein nanorod can reach 84.17 percent at most. And the encapsulation efficiency and the drug loading rate are relatively stable. In-vitro drug release tests prove that the release rate of the drug reaches 93.0 percent, and the cumulative release rate of the drug after 24 hours of dialysis is 67.54 percent. In addition, the nano drug-carrying system has large adhesion and small particle size, which is not only beneficial to the increase of retention when local drug is applied, but also beneficial to the increase of contact time and contact area between the drug and the gastrointestinal wall and the improvement of bioavailability of oral drug absorption, so the nano drug-carrying system can be used as a new dosage form of a sustained-release drug, can prolong the circulation time in the body and has good effect. The method of the invention provides a theoretical basis for clarifying certain pathogenesis and the research of dosage forms of new drugs, and baicalein has wider application prospect.
Drawings
FIG. 1 is transmission electron microscope image of pectic baicalein;
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention.
Example 1
1. Test protocol
A preparation method of a baicalein drug-loaded nanorod comprises the following steps:
(1) 7.957g of sodium dihydrogen phosphate and 17.549g of disodium hydrogen phosphate powder are respectively weighed, are respectively dissolved in a proper amount of distilled water, are moved to a 500mL volumetric flask, are diluted by the distilled water to be constant volume to 500mL, and then the phosphoric acid buffer solution with the pH value of 6.7 is obtained;
(2) accurately weighing 0.01g of baicalein and 0.10g of pectin, adding into a 50mL volumetric flask, adding magnetons, adding 20mL of PBS solution with pH of 6.7, immersing in a 50 ℃ constant-temperature water bath, magnetically stirring, and heating for 0.5 hour; preparation of Ca (OH)2Solution (0.02mol/L), dropwise adding 8mL into the solution, and stirring at 50 ℃ for 1 hour; then, adding NaHCO3The solution (0.03mol/L) was added dropwise to the above reaction system in an amount of 8mL, stirred at 50 ℃ for another 3 hours, and then 0.010g of baicalein was added. The mixture was stirred continuously for 24 hours at 50 ℃ and then rapidly cooled for 0.5 hours in a water bath at 20 ℃ at normal temperature. Finally, the reaction mixture is filled into a dialysis bag and dialyzed in 500ml PBS solution at 20 ℃ for 24 hours, so that the drug-loaded nano-rod can be obtained.
2. Determination of encapsulation efficiency
The encapsulation efficiency is an important factor for evaluating the preparation process and the quality of the preparation. The entrapment rate is the proportion of the drug quantity entrapped in the liposome to the total drug dosage, and the specific determination method of the entrapment rate in the experiment is as follows: precisely measuring 1mL of a drug-loaded nanorod sample solution, placing the drug-loaded nanorod sample solution in a dialysis bag as an internal solution, taking a PBS (phosphate buffer solution) with pH of 7.4 as an external solution, changing water every 12 hours, and dialyzing for 24 hours. After dialysis, the internal liquid is taken out, 9mL of demulsifier (ethanol: ether is 7: 2) is added for demulsification, the absorbance of curcumin is measured, and the measured absorbance of a sample is substituted into an absorbance-concentration relation equation:
a 0.000174354+0.03087c,
the concentration of the drug-loaded nanorod can be measured, and then a formula is calculated according to the encapsulation efficiency:
the encapsulation efficiency (EE%) -the amount of drug encapsulated in the system/total amount administered x 100%, was calculated as shown in table 1 below.
Table 1: encapsulation efficiency of the sample
And (3) measuring results: the encapsulation efficiency is 84.17% at most.
3. Determination of drug loading
Simultaneously carrying out three groups of tests, taking 3mL of sample by using a micro-sampler, placing the sample in a culture dish, freeze-drying the sample in a freeze dryer for 2-3 days, taking out the sample after freeze-drying, scraping freeze-dried powder, weighing in an electronic balance to obtain the total weight of the drug-carrying nanorod, and calculating the drug-carrying capacity according to the following formula:
the drug loading (DL%) -the content of the drug in the microsphere or vesicle/the total weight of the microsphere or vesicle x 100%
The measurement results are shown in Table 2.
Table 2: drug loading of samples
| Loading capacity/% | Loading capacity/% | Loading capacity/% | Mean value/%) | |
| Sample (I) | 18.74 | 16.88 | 18.54 | 18.05±5.65 |
And (3) measuring results: the drug loading was 18.74% maximum.
4. Drug release test of baicalein
Carrying out pure baicalein dialysis:
accurately weighing 0.100g of pure baicalein by using an electronic balance, dissolving the pure baicalein in a PBS solution with the pH value of 6.7 in a 100mL volumetric flask, and preparing into 1mg/mL baicalein standard solution. 2.0mL of the solution was pipetted into the dialysis bag, and then the bag containing the standard solution was placed into 100mL of PBS solution with pH 6.7 to release the drug while shaking in a 37 ℃ constant temperature air bath shaker.
Sampling at intervals, measuring the absorbance of the medicine in the PBS solution outside the dialysis bag, and recording and calculating the cumulative release amount of the baicalein at each time interval.
② the drug release test of baicalein nano-rod:
nanorods with pectin as the carrier: preparing a nano drug-loaded solution of 1mg/mL, simultaneously carrying out three groups of tests, moving 2.0mL by a pipette, placing the solution into a dialysis bag, placing the sealed dialysis bag into 100mL of PBS solution with the pH value of 6.7, simultaneously shaking the solution in a 37 ℃ air bath constant temperature oscillator, sampling at intervals to measure the absorbance of a sample outside the dialysis bag, simultaneously injecting a new PBS solution into a wide-mouth bottle, recording and calculating the cumulative drug release amount at each time, drawing a baicalein nanorod cumulative drug release amount curve, and recording and calculating the release degree of the drug. The results are shown in table 3 below.
Table 3: pectin carrier baicalein drug release test result table
| Numbering | Time interval/h | absorbance/A | Concentration/. mu.g/mL | Cumulative release rate/%) |
| 1 | 0 | 0 | 0 | 0 |
| 2 | 1 | 0.109 | 3.525 | 17.625 |
| 3 | 2 | 0.184 | 5.952 | 29.76 |
| 4 | 4 | 0.262 | 8.476 | 42.38 |
| 5 | 6 | 0.304 | 9.845 | 49.225 |
| 6 | 8 | 0.335 | 10.854 | 54.27 |
| 7 | 12 | 0.354 | 11.478 | 57.39 |
| 8 | 16 | 0.370 | 11.986 | 59.93 |
| 9 | 20 | 0.401 | 12.974 | 64.87 |
| 10 | 24 | 0.417 | 13.508 | 67.54 |
And (3) measuring results: after the baicalein standard solution is released in the PBS buffer solution for 2 hours, the medicine permeates the dialysis bag for 1.86mg, and the release degree reaches 93.0%. The drug cumulative release rate of the pectin carrier baicalein nanorods after dialysis for 24 hours is 67.54%.
5. Stability test
The diluted samples 1 and 2 were stored for two weeks at room temperature in the dark, and the presence of precipitate or flocculate was observed, and the absorbance was measured in an ultraviolet-visible spectrophotometer, and the change in encapsulation efficiency was calculated, the results are shown in table 4.
Table 4: baicalein stability test result table
| Presence or absence of floc | Encapsulation efficiency/% before standing | Envelope ratio after two weeks/%) | |
| Sample 1 | Is free of | 83.44 | 77.26 |
| Sample 2 | Is free of | 76.19 | 71.53 |
And (3) measuring results: the prepared nano rod does not generate flocculent precipitate after being stored at room temperature, and the encapsulation efficiency is reduced by about 5 percent. It is known that there is significant leakage of the drug, especially when the temperature is increased. If the prepared nano suspension is added with a freeze-drying protective agent, after freeze-drying, the nano suspension is placed for 1 month, almost no leakage occurs, and the stability is better.
6. High resolution transmission electron microscopy detection
The prepared nano drug-loaded solution sample is observed in a transmission electron microscope, and the particle size and the shape are observed, and the result is shown in figure 1.
Fig. 1 is a transmission electron microscope image of a nano drug-loading system using pectin as a carrier, and it can be seen that the appearance of a single pectin carrier nanorod structure is spindle-shaped, the particle size is between 100 nm and 300nm, and the single pectin carrier nanorod structure has strong affinity for water molecules, thereby providing a basis and possibility for constructing drug-loading systems with different forms.
The foregoing is to be considered as illustrative and not limiting of the scope of the invention. The scope of the invention is defined by the appended claims, and it will be apparent to those skilled in the art that certain insubstantial modifications and adaptations of the invention can be made without departing from the spirit and scope of the invention.
Claims (3)
1. A preparation method of baicalein drug-loaded nanorods is characterized in that: the method comprises the following steps:
step one, respectively weighing 0.01g of baicalein and 0.1g of pectin, adding into a glass container, adding 20mL of phosphoric acid buffer solution, soaking the glass container in a constant-temperature water bath at 50 ℃, and uniformly mixing by magnetic stirring for 0.5h to obtain a mixed solution I;
step two, dropwise adding 8mL of Ca (OH) with the concentration of 0.02mol/L into the mixed solution I2Heating the aqueous solution at 50 deg.C for 1 hr; then gradually get rid of8mL of NaHCO with a concentration of 0.03mol/L are added dropwise3Heating the aqueous solution for 3 hours at 50 ℃ to obtain a mixed solution II;
step three, adding 0.01g of baicalein into the mixed solution II, continuously magnetically stirring for 24 hours at the temperature of 50 ℃, and then placing the mixture into a water bath at the normal temperature of 20 ℃ for cooling for 0.5 hour to obtain a reaction mixture; and putting the reaction mixture into a dialysis bag, and dialyzing in 500mL of phosphoric acid buffer solution at 20 ℃ for 24h to obtain the baicalein drug-loaded nanorod.
2. The method for preparing the baicalein drug-loaded nanorod according to claim 1, characterized in that: the pH of the phosphoric acid buffer solution was 6.7.
3. The method for preparing baicalein drug-loaded nanorods as claimed in claim 1 or 2, characterized in that: the preparation method of the phosphoric acid buffer solution comprises the following steps: 7.957g of sodium dihydrogen phosphate and 17.549g of disodium hydrogen phosphate powder are respectively weighed and respectively dissolved in distilled water, and then the solution is transferred to a 500mL volumetric flask and diluted with distilled water to a constant volume of 500mL, thus obtaining the phosphoric acid buffer solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811554429.XA CN109432012B (en) | 2018-12-18 | 2018-12-18 | Preparation method of baicalein drug-loaded nanorod |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811554429.XA CN109432012B (en) | 2018-12-18 | 2018-12-18 | Preparation method of baicalein drug-loaded nanorod |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109432012A CN109432012A (en) | 2019-03-08 |
| CN109432012B true CN109432012B (en) | 2021-02-23 |
Family
ID=65559399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811554429.XA Active CN109432012B (en) | 2018-12-18 | 2018-12-18 | Preparation method of baicalein drug-loaded nanorod |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109432012B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111638188A (en) * | 2020-05-27 | 2020-09-08 | 东北农业大学 | Method for measuring entrapment rate of lipid liposome |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1744827A (en) * | 2003-01-31 | 2006-03-08 | 帝斯曼知识产权资产管理有限公司 | The composition that comprises the novelty of carotenoid |
| CN104173292A (en) * | 2014-09-09 | 2014-12-03 | 重庆医科大学 | Novel insoluble drug-loading calcium pectate nanoparticle and preparation method thereof |
-
2018
- 2018-12-18 CN CN201811554429.XA patent/CN109432012B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1744827A (en) * | 2003-01-31 | 2006-03-08 | 帝斯曼知识产权资产管理有限公司 | The composition that comprises the novelty of carotenoid |
| CN104173292A (en) * | 2014-09-09 | 2014-12-03 | 重庆医科大学 | Novel insoluble drug-loading calcium pectate nanoparticle and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| Insulin-Loaded Calcium Pectinate Nanoparticles: Effects of Pectin Molecular Weight and Formulation pH;Cheng K.，et al.;《DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY》;20041231;第30卷(第4期);第359–367页 * |
| 多糖作为载体在5-氨基水杨酸口服结肠定位***中的研究进展;刘慧敏 等;《实用药物与临床》;20171231;第20卷(第12期);第1445-1449页 * |
| 注射用黄芩素乳剂及冻干粉针剂的制备;张晓博;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20160315(第03期);E057-45:第1-5,9,33页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109432012A (en) | 2019-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103610642B (en) | A kind of liposome and preparation method who seals Epigallo-catechin gallate (EGCG) | |
| Bhavsar et al. | Systematic investigation of in vitro and in vivo safety, toxicity and degradation of mesoporous silica nanoparticles synthesized using commercial sodium silicate | |
| CN107412779B (en) | Preparation method of antitumor drug carrier with physical targeting | |
| CN111718465B (en) | Poly-dithioacetal and preparation method and application thereof | |
| CN109260177B (en) | Preparation method and application of berberine hydrochloride compound nanoparticles | |
| CN114452268B (en) | Preparation method of mesoporous polydopamine anthocyanin-carrying nanoparticle | |
| CN103961712A (en) | Superparamagnetic ferroferric oxide nano particle drug carrier, preparation method and application thereof | |
| CN100560137C (en) | Bacillus nanometer magnetosome of a kind of carrier band primary amino medicine and preparation method thereof | |
| CN109432012B (en) | Preparation method of baicalein drug-loaded nanorod | |
| Qian et al. | Application of micro/nanomaterials in adsorption and sensing of active ingredients in traditional Chinese medicine | |
| CN109481404B (en) | Preparation method of pH-sensitive imidazole liposome | |
| CN104161745A (en) | Method for preparing nanometer iron citrate liposome | |
| CN112830924B (en) | Preparation of rhein and isoquinoline alkaloid anti-multiple drug resistant staphylococcus aureus carrier-free nano-drug | |
| CN112704743A (en) | Sea cucumber saponin mesoporous silica nanocomposite for injection and preparation method and application thereof | |
| CN101036785A (en) | Chitosan nanoparticles oral preparations of hepatitis vaccine | |
| CN105905912A (en) | High-yield mesoporous silica nano-particle and folic acid targeting modification method thereof | |
| CN107913249B (en) | Composition, nano micelle containing composition and application | |
| CN114652820B (en) | Cationic liposome nanoparticle and preparation method and application thereof | |
| CN109453139A (en) | A kind of LBL self-assembly nano-carrier and preparation method comprising 5 FU 5 fluorouracil | |
| CN102499943B (en) | Preparation and anti-tumor activity of polymer wrapped heteropoly acid nano hybrid material | |
| CN108451931B (en) | PAH/F polyelectrolyte compound nano-carrier and preparation method thereof | |
| CN107496936A (en) | A kind of both sexes small molecule self assembly targeted nanoparticles drug-loading system and preparation method thereof | |
| CN107029241B (en) | Triptolide-casein nano-composite as well as preparation method and application thereof | |
| CN117085001B (en) | Preparation method and application of dual-targeting core-shell structure nano drug-loaded particles | |
| CN108619098B (en) | Raltitrexed pH sensitive liposome and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |